tbuckley/cabot-search huggingface dataset:
18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence
Authors: Nina Jehanno, Thibaut Cassou-Mounat, Hamid Mammar, Marie Luporsi, Virginie Huchet
Journal: Clinical Nuclear Medicine (2019)

We report the case of a 50-year-old man, with previous history of grade 3 intracranial hemangiopericytoma with initial complete surgical resection, addressed for local recurrence. Surgical revision performed 18 months after initial surgery allowed only partial resection, leaving residual disease along the optic nerve. Complementary radiotherapy with proton was decided. F-FDG PET/CT and F-choline PET/CT were both performed for treatment planning. F-FDG PET showed no uptake of the residual tumor, whereas F-choline depicted highly metabolic residual disease uptake with excellent delineation of local recurrence. F-choline PET/CT appears as a useful PET tracer for hemagiopericytoma imaging.
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association
Authors: Umberto Campia, Javid J. Moslehi, Laleh Amiri-Kordestani, Ana Barac, Joshua A. Beckman, David D. Chism, Paul Cohen, John D. Groarke, Joerg Herrmann, Carolyn M. Reilly, Neal L. Weintraub
Journal: Circulation (2019)

Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with cancer and cancer survivors are at increased risk of vascular disease for a number of reasons. First, many new cancer therapies, including several targeted therapies, are associated with vascular and metabolic complications. Second, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for thromboembolic events. Finally, recent data suggest that common modifiable and genetic risk factors predispose to both malignancies and cardiovascular disease. Vascular complications in patients with cancer represent a new challenge for the clinician and a new frontier for research and investigation. Indeed, vascular sequelae of novel targeted therapies may provide insights into vascular signaling in humans. Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. This novel approach realizes the goal of providing superior care through the creation of cardio-oncology consultative services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.
Letter to Editor: Repair or Prevent: What Is the Real Impact of Normothermic Machine Perfusion in Liver Transplantation?
Authors: Andrea Schlegel, Philipp Dutkowski
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the paper by Jassem et al.,1 which provides detailed gene expression profiles of human livers during normothermic machine perfusion (NMP), compared with conventional cold storage. The authors should be congratulated on this extensive analysis, which shows for the first time transcriptional changes during any form of reperfusion under normothermic conditions.1 However, we would like to add a few critical comments. The authors analyzed liver samples at the end of cold storage or NMP, and after graft implantation. First, although changes in gene alteration during NMP are certainly relevant, we would like to mention that all livers in the NMP group underwent prolonged normothermic reperfusion on the device before the first biopsy, obtained after a considerable contact of liver cells with fully oxygenated blood. Another biopsy, for example, 1 hour after the start of NMP, would be important to confirm the hypothesis that NMP is in fact actively leading to down‐regulation of inflammatory pathways (Fig. 1). Importantly, for kidneys, lungs, hearts, and livers, current research has shown the opposite.2 Second, proper comparisons of NMP and cold storage require assessment of reperfusion injury after a similar duration of normothermic reperfusion, either on the NMP device or after reperfusion of cold stored livers in situ.1 (Fig. 1) Expectedly, gene expression profiles between NMP and cold storage appear very different, and parallel previous assessments after transplantation of subnormothermically perfused livers.4 Third, the results imply that NMP after cold ischemia triggers inferior outcome.1 Consistently, Watson et al. have demonstrated a clear inflammatory response when NMP was performed after significant cold storage in livers with a cumulative high risk.5 It may therefore be important to emphasize that especially high‐risk livers need either upfront NMP or other machine perfusion techniques targeting metabolic changes before implantation, such as hypothermic oxygenated perfusion or controlled oxygenated rewarming.2Figure 1: Overview of liver preservation and timepoints of gene expression profile analysis comparing upfront normothermic machine perfusion and cold storage.Based on this, we believe that the presented data show a minimization of inflammation and necrosis through replacement of cold ischemia by sophisticated NMP techniques. However, we do not think the data support the conclusion that NMP itself leads to down‐regulations of inflammatory pathways.
Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment
Authors: K. Weibring, C. Nord, O. Ståhl, J. Eberhard, K. Sandberg, H. Johansson, S. Arver, A. Giwercman, G. Cohn-Cedermark
Journal: Annals of Oncology (2019)

BackgroundLittle is known regarding sperm production following adjuvant treatment in testicular cancer (TC) clinical stage I (CS I) patients.Patients and methodsA total of 182 TC patients aged 18–50 years were prospectively included during 2001–2006 at any given time within 5 years of orchiectomy. Semen samples were delivered postorchiectomy but before further treatment, 6, 12, 24, 36 and 60 months (T0–T60) after completed therapy. Total sperm number (TSN) and sperm concentration (SC) were used as measurements of testicular function. Four groups according to treatment modality were identified; Radiotherapy; To a total dose of 25.2 Gy to the infradiaphragmal paraaortic and ipsilateral iliac lymph nodes (RT, N = 70), one cycle of adjuvant BEP (bleomycin, etoposide, cisplatin, 5 day regimen) (BEP, N = 62), one cycle of adjuvant carboplatin AUC 7 (Carbo, N = 22), and patients managed by surveillance (SURV, N = 28).ResultsIn the cross-sectional analysis, a significant but transient drop in mean TSN and mean SC (T0–T60) was seen at T6 after radiotherapy. Apart from a significant increase in mean SC at T12 compared with baseline, no significant differences were observed in the other treatment groups. In 119 patients delivering 3 or more samples, values in TSN and SC were rather stable over time. Azoospermic patients (N = 11) were observed in most treatment groups except for in the BEP group. During follow-up, one azoospermic patient belonging to the Carbo group became normospermic.ConclusionsNo clinically significant long-term effect on TSN or SC associated with adjuvant treatment in TC CSI patients was found. However, as patients may have low sperm counts before orchiectomy as well as after adjuvant treatment, we offer sperm banking before orchiectomy as assisted reproductive measures may be necessary regardless of treatment given.
Influenza Vaccination Coverage Among Health Care Personnel — United States, 2017–18 Influenza Season
Authors: Carla L. Black, Xin Yue, Sarah W. Ball, Rebecca V. Fink, Marie A. de Perio, A. Scott Laney, Walter W. Williams, Samuel B. Graitcer, Amy Parker Fiebelkorn, Peng-Jun Lu, Rebecca Devlin
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

The Advisory Committee on Immunization Practices (ACIP) recommends that all health care personnel receive an annual influenza vaccination to reduce influenza-related morbidity and mortality among health care personnel and their patients and to reduce absenteeism among health care personnel (1-4). CDC conducted an opt-in Internet panel survey of 2,265 U.S. health care personnel to estimate influenza vaccination coverage among these persons during the 2017-18 influenza season. Overall, 78.4% of health care personnel reported receiving influenza vaccination during the 2017-18 season, similar to reported coverage in the previous four influenza seasons (5). As in previous seasons, coverage was highest among personnel who were required by their employer to be vaccinated (94.8%) and lowest among those working in settings where vaccination was not required, promoted, or offered on-site (47.6%). Health care personnel working in long-term care settings, the majority of whom work as assistants or aides, have lower influenza vaccination coverage than do health care personnel working in all other health care settings, which puts the elderly in long-term settings at increased risk for severe complications for influenza. Implementing workplace strategies shown to improve vaccination coverage among health care personnel, including vaccination requirements and active promotion of on-site vaccinations at no cost, can help ensure health care personnel and patients are protected against influenza (6). CDC's long-term care web-based toolkit* provides resources, strategies, and educational materials for increasing influenza vaccination among health care personnel in long-term care settings.
Abstract 11804: GsMTx4-D is a Cardioprotectant Against Myocardial Infarction During Ischemia and Reperfusion
Authors: Jinli Wang, Yina Ma, Frederick Sachs, Thomas Suchyna, Ji Li
Journal: Circulation (2016)

Introduction: GsMTx4 is a selective inhibitor of cationic mechanosensitive ion channels (MSCs) and has helped establish the role of MSCs in cardiac physiology. Inhomogeneous local mechanical stresses due to hypercontracture and swelling, likely induce elevated MSC activity that can contribute to the cation imbalance observed during ischemic reperfusion injury. This study was to determine if the D enantiomer of GsMTx4 can act as a cardioprotectant during ischemia and reperfusion and to evaluate its effects on cation influx and inflammatory kinases that are regulated by this influx. Hypothesis: GsMTx4 protects heart from ischemic insults through inhibiting the cationic mechanosensitive ion channels. Methods: Ischemia and reperfusion in the mouse heart involved ligating a coronary artery followed by release of the ligature. Results: GsMTx4-D was administered by acute intravenous injection during the ischemic event. Based on pharmacokinetic studies, GsMTx4-D dosage was set to achieve expected plasma concentrations between 50-5000 nM and heart tissue concentrations between 1-200 nM. Relative to vehicle injected animals, GsMTx4-D reduced infarct area by ~40% for acute and pretreated animals, and for both 20 and 45 min ischemic challenges. Many indicators of cardiac output were indistinguishable from sham-treated control hearts after GsMTx4-D treatment and most showed improvement at both 4 and 48 hrs post ischemia. Premature ventricular beats immediately following reperfusion were also significantly reduced by intravenous injections of GsMTx4-D. Myocytes cultured under hypoxic conditions treated with 10 μM GsMTx4-D showed improved contractility and near normal contraction-related Ca 2+ influx. GsMTx4-D inhibited indicators of ischemic damage such as the apoptotic signaling system JNK/c-Jun, but also inhibited the energy response signaling system Akt kinase. Conclusions: GsMTx4-D is a potent cardioprotectant that decreases infarct area, increases cardiac output and decreases arrhythmias that are caused by ischemia and reperfusion. GsMTx4-D improved cardiomyocyte function and suppresses apoptosis, making it potentially useful in multidrug strategies to treat ischemic heart disease.
Reviewer acknowledgment 2014
Authors: Otis W. Brawley, Ted Gansler
Journal: CA A Cancer Journal for Clinicians (2014)

The Editors of CA depend on the wisdom and advice of many experts in deciding which topics to pursue, which manuscripts to publish, and what modifications to make to ensure medical and scientific accuracy and suitability for our readers. We thank our Deputy Editor and Associate Editors, who have performed these services for us in the past year. We are also greatly indebted to the expertise, dedication, and expeditious response of the following individuals for reviewing at least one and, in some cases, many manuscripts for the journal from July 1, 2013, to June 30, 2014. Albers, James Ballman, Karla Berg, Christine Boyiadzis, Michael Checkoway, Harvey Chlebowski, Rowan Cleary, Margot Copperman, Alan Cornblath, David Delman, Keith Duffy, Sonia Dy, Grace Formenti, Silvia Freemantle, Sarah Gangwisch, James Gapstur, Susan Gaudet, Mia Glass, Thomas Halperin, William Hansen, Johnni Jessup, John Ju, Jingfang Kirkwood, John Korc, Murray Lawson, David Mahoney, Martin Maitin-Shepard, Melissa Malcolm, Arnold Markowitz, Steven McKee, Andrea Pantel, Klaus Patterson, Ruth Roach, Mack Salner, Andrew Saslow, Debbie Schover, Leslie Smith, Benjamin Smith, Thomas Stevens, Vicky Studts, Jamie Tammemägi, Martin Tattersall, Martin Torres, Mylin Vinluan, Monica
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Authors: Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri, Neil Chanchlani, Neel M Heerasing, Peter Hendy, Simeng Lin, Daniel R Gaya, J R Fraser Cummings, Christian P Selinger, Charlie W Lees, Ailsa L Hart, Miles Parkes, Shaji Sebastian, John C Mansfield, Peter M Irving, James Lindsay, Richard K Russell, Timothy J McDonald, Dermot McGovern, James R Goodhand, Tariq Ahmad, Vinod Patel, Zia Mazhar, Rebecca Saich, Ben Colleypriest, Tony C Tham, Tariq H Iqbal, Vishal Kaushik, Senthil Murugesan, Salil Singh, Sean Weaver, Cathryn Preston, Assad Butt, Melissa Smith, Dharamveer Basude, Amanda Beale, Sarah Langlands, Natalie Direkze, Miles Parkes, Franco Torrente, Juan De La Revella Negro, Chris Ewen MacDonald, Stephen M Evans, Anton V J Gunasekera, Alka Thakur, David Elphick, Achuth Shenoy, Chuka U Nwokolo, Anjan Dhar, Andrew T Cole, Anurag Agrawal, Stephen Bridger, Julie Doherty, Sheldon C Cooper, Shanika de Silva, Craig Mowat, Phillip Mayhead, Charlie Lees, Gareth Jones, Tariq Ahmad, James W Hart, Daniel R Gaya, Richard K Russell, Lisa Gervais, Paul Dunckley, Tariq Mahmood, Paul J R Banim, Sunil Sonwalkar, Deb Ghosh, Rosemary H Phillips, Amer Azaz, Shaji Sebastian, Richard Shenderey, Lawrence Armstrong, Claire Bell, Radhakrishnan Hariraj, Helen Matthews, Hasnain Jafferbhoy, Christian P Selinger, Veena Zamvar, John S De Caestecker, Anne Willmott, Richard Miller, Palani Sathish Babu, Christos Tzivinikos, Stuart L Bloom, Guy Chung-Faye, Nicholas M Croft, John ME Fell, Marcus Harbord, Ailsa Hart, Ben Hope, Peter M Irving, James O Lindsay, Joel E Mawdsley, Alistair McNair, Kevin J Monahan, Charles D Murray, Timothy Orchard, Thankam Paul, Richard Pollok, Neil Shah, Sonia Bouri, Matt W Johnson, Anita Modi, Kasamu Dawa Kabiru, B K Baburajan, Bim Bhaduri, Andrew Adebayo Fagbemi, Scott Levison, Jimmy K Limdi, Gill Watts, Stephen Foley, Arvind Ramadas, George MacFaul, John Mansfield, Leonie Grellier, Mary-Anne Morris, Mark Tremelling, Chris Hawkey, Sian Kirkham, Charles PJ Charlton, Astor Rodrigues, Alison Simmons, Stephen J Lewis, Jonathon Snook, Mark Tighe, Patrick M Goggin, Aminda N De Silva, Simon Lal, Mark S Smith, Simon Panter, J R Fraser Cummings, Suranga Dharmisari, Martyn Carter, David Watts, Zahid Mahmood, Bruce McLain, Sandip Sen, Anna J Pigott, David Hobday, Emma Wesley, Richard Johnston, Cathryn Edwards, John Beckly, Deven Vani, Subramaniam Ramakrishnan, Rakesh Chaudhary, Nigel J Trudgill, Rachel Cooney, Andy Bell, Neeraj Prasad, John N Gordon, Matthew J Brookes, Andy Li, Stephen Gore
Journal: The Lancet. Gastroenterology & hepatology (2019)
Meta-analysis of 94 epidemiologic studies on cigarette smoking and liver cancer
Authors: Yuan-Chin Lee, Catherine Cohet, Yu-Ching Yang, Mia Hashibe, Kurt Straif
Journal: Cancer Research (2007)

87  Introduction: The incidence of liver cancer varies greatly by geographic region. The age standardized rates (ASR) among men are 5.3 in North America, 6.2 in Western Europe, and 36.9 in East Asia. The ASRs for women are 1.9 in North America, 1.7 in Western Europe, and 13.3 in East Asia. Several factors, such as HBV and HCV infection, alcohol consumption and aflatoxin-B1-contaminated food, have been established as risk factors for liver cancer. The IARC Monograph on tobacco smoking concluded there is sufficient evidence in humans that cigarette smoking causes liver cancer. However, the United States Surgeon General’s report concluded the evidence is suggestive but not sufficient to infer a causal relationship between smoking and liver cancer. A meta-analysis of published epidemiologic studies may help to clarify the potential association.  Methods: We conducted a systematic literature search for epidemiologic studies on liver cancer and cigarette smoking. Meta-relative risks (mRR) were calculated to combine study specific risk estimates overall, for various strata and for dose-response data. Heterogeneity, publication bias and influence analyses were performed.  Results: A total of 38 cohort studies (including 4 nested case-control studies) and 56 case-control studies investigated the association of cigarette smoking and liver cancer risk. Compared to never smokers, the adjusted mRRs for liver cancer were 1.52 (95% confidence interval [CI] = 1.37-1.68) for current smokers and 1.20 (95% CI = 1.06-1.36) for former smokers. For men, the adjusted mRRs were 1.65 (95% CI = 1.40-1.96) for current smokers and 1.41 (95% CI = 1.10-1.81) for former smokers. For women, the adjusted mRRs were 1.92 (95% CI = 1.36-2.71) for current smokers and 1.39 (95% CI = 0.74-2.61) for former smokers. When stratified by geographic region, adjusted mRRs for current smoking were 1.68 (95% CI = 0.89-3.17) for the Americas, 1.26 (95% CI = 0.65-2.46) for Europe, and 1.55 (95% CI = 1.35-1.78) for Asia. In addition, the associations among current smokers appeared to be consistent with the overall mRR regardless of study design (case-control and cohort), sample size, and publication period (1966-1990 vs. 1991-2006). The mRRs for adjusted estimates were similar to those for crude estimates. When we restricted the studies to those adjusting for alcohol, HBV or HCV, the magnitude of effect for current smoking remained similar. Using Egger’s test, there was no suggestion of publication bias (p value = 0.471). Dose-response trends were observed with adjusted mRRs of 1.6 for every 20 cigarettes per day increase and 1.3 for every 40 pack-years increase of smoking (p for trend = 0.0099 and 0.0499, respectively).  Conclusion: Our meta-analysis supports the association between cigarette smoking and liver cancer risk. For current smoking, major differences in liver cancer risk were not suggested by gender, geographic region, study design or time period of publication.
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
Authors: Jonas Hugosson, Monique J. Roobol, Marianne Månsson, Teuvo L.J. Tammela, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Sigrid V. Carlsson, Kirsi M. Talala, Hans Lilja, Louis J. Denis, Franz Recker, Alvaro Paez, Donella Puliti, Arnauld Villers, Xavier Rebillard, Tuomas P. Kilpeläinen, Ulf H. Stenman, Rebecka Arnsrud Godtman, Karin Stinesen Kollberg, Sue M. Moss, Paula Kujala, Kimmo Taari, Andreas Huber, Theodorus van der Kwast, Eveline A. Heijnsdijk, Chris Bangma, Harry J. De Koning, Fritz H. Schröder, Anssi Auvinen
Journal: European Urology (2019)
Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia
Authors: Christina Wu, Emanuela M. Ghia, Fitzgerald Lao, Minya Pu, Karen Messer, Laura Z. Rassenti, Thomas J. Kipps, Dennis A. Carson, Michael Y. Choi
Journal: Blood (2018)
Clinical highlights from the National Cancer Data Base: 1995
Authors: G. D. Steele, L. M. Jessup, D. P. Winchester, G. P. Murphy, H. R. Menck
Journal: CA A Cancer Journal for Clinicians (1995)

The National Cancer Data Base, a joint project of the American Cancer Society and the American College of Surgeons Commission on Cancer, provides a mechanism for periodic assessment of hospital-based cancer patient care. From the National Cancer Data Base's annual summary, health care professionals can evaluate trends in patient care to make more efficient treatment decisions. This article provides a first look at highlights of the 1995 annual summary.
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients
Authors: Claudia Sommerer, Barbara Suwelack, Duska Dragun, Peter Schenker, Ingeborg A. Hauser, Oliver Witzke, Christian Hugo, Nassim Kamar, Pierre Merville, Martina Junge, Friedrich Thaiss, Björn Nashan, Eric Almartine, Jacques Dantal, Duska Dragun, Thorsten Feldkamp, Ingeborg A. Hauser, Marc Hazzan, Nils Heyne, Christian Hugo, Nassim Kamar, Philippe Lang, Frank Lehner, Yannick Le Meur, Jens Lutz, Pierre Merville, Emmanuel Morelon, Bruno Moulin, Christiane Mousson, Anja Muehlfeld, Björn Nashan, Przemyslaw Pisarski, Eric Rondeau, Peter Schenker, Claudia Sommerer, Barbara Suwelack, Friedrich Thaiss, Antoine Thierry, Michael Wiesener, Oliver Witzke
Journal: Kidney International (2019)

This is a randomized trial (ATHENA study) in de novo kidney transplant patients to compare everolimus versus mycophenolic acid (MPA) with similar tacrolimus exposure in both groups, or everolimus with concomitant tacrolimus or cyclosporine (CsA), in an unselected population. In this 12-month, multicenter, open-label study, de novo kidney transplant recipients were randomized to everolimus with tacrolimus (EVR/TAC), everolimus with CsA (EVR/CsA) or MPA with tacrolimus (MPA/TAC), with similar tacrolimus exposure in both groups. Non-inferiority of the primary end point (estimated glomerular filtration rate [eGFR] at month 12), assessed in the per-protocol population of 338 patients, was not shown for EVR/TAC or EVR/CsA versus MPA/TAC. In 123 patients with TAC levels within the protocol-specified range, eGFR outcomes were comparable between groups. The mean increase in eGFR during months 1 to 12 post-transplant, analyzed post hoc, was similar with EVR/TAC or EVR/CsA versus MPA/TAC. The incidence of treatment failure (biopsy proven acute rejection, graft loss or death) was not significant for EVR/TAC but significant for EVR/CsA versus MPA/TAC. Most biopsy-proven acute rejection events in this study were graded mild (BANFF IA). There were no differences in proteinuria between groups. Cytomegalovirus and BK virus infection were significantly more frequent with MPA/TAC. Thus, everolimus with TAC or CsA showed comparable efficacy to MPA/TAC in de novo kidney transplant patients. Non-inferiority of renal function, when pre-specified, was not shown, but the mean increase in eGFR from month 1 to 12 was comparable to MPA/TAC.